

AMENDMENT TO THE CLAIMS

1. (Currently Amended) A method for preventing neuronal apoptosis by inhibiting the biological activity of transforming growth factor- β_1 (TGF- β_1), transforming growth factor- β_2 (TGF- β_2) and/or transforming growth factor- β_3 (TGF- β_3) on damaged neurons in a cerebral disorder, said method comprising :

providing a patient having damaged neurons, said damaged neurons —caused by a cerebral disorder,—; and

treating said damaged neurons in said patient with a first compound that prevents neuronal apoptosis by —inhibiting the biological activity of TGF- β_1 , TGF- β_2 and/or TGF- β_3 on said damaged neurons.

2-4. (Cancelled)

5. (Currently Amended) A pharmaceutical composition comprising:

a first compound for preventing neuronal apoptosis by inhibiting the biological activity of TGF- β_1 , TGF- β_2 and/or TGF- β_3 ~~TGF- β~~ on damaged neurons caused by a cerebral disorder—; and

a second compound for disintegrating blood clots, wherein said first and second compounds are formulated in a pharmaceutically acceptable carrier.

6. (Currently Amended) The pharmaceutical composition —of claim 5, wherein said first compound is an antibody directed to TGF- β_1 , TGF- β_2 and/or TGF- β_3 ~~TGF- β~~ or —said first compound —has a —binding site of a TGF- β_1 , TGF- β_2 and/or TGF- β_3 ~~TGF- β~~ receptor.

7. (Cancelled)

8. (Currently Amended) The pharmaceutical composition —of claim 5, wherein said second compound is selected from the group consisting of urokinase, thrombin, and tissue plasminogen activator.

9-13. (Cancelled)

14. (Currently Amended) The method of claim 1, wherein said first compound ~~preventing neuronal apoptosis by inhibiting the biological activity of TGF- β~~ is selected from the group consisting of —an ~~antibody to~~inhibitor of TGF- β 1, TGF- β 2 and/or TGF- β 3~~TGF- β ,~~ —an antagonist to TGF- β 1, TGF- β 2 and/or TGF- β 3~~TGF- β ,~~ and —a composition altering TGF- β 1, TGF- β 2 and/or TGF- β 3~~TGF- β .~~

15. (Currently Amended) The method of claim 14, wherein said first compound is selected from the group consisting of ~~TGFC- β inhibitors~~an antibody directed to TGF- β 1, TGF- β 2 and/or TGF- β 3, ~~and~~ a composition —having —a binding site of a TGF- β 1, TGF- β 2 and/or TGF- β 3~~TGF- β receptor, and TGF- β RII/Fe chimeric protein.~~

16. (Previously Presented) The method of claim 1, wherein said method further comprises treating said patient with a second compound for disintegrating blood clots.

17. (Previously Presented) The method of claim 16, wherein said second compound is selected from the group consisting of urokinase, thrombin, and tissue plasminogen activator.

18. (Previously Presented) The method of claim 1 or 17, wherein said first or second compound is administered intravenously, orally or intracerebrally.